the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |
RSS Feed
Pharmaceutical
Bone Disease Treatment
Cancer
Clinical Trial
DDS
Diabetes
Drug Discovery
eHealthcare
Feminine Hygiene
Gastrointestinal
Generic Drugs
Hematology
Hepatitis
Hypertension
In Vitro Diagnostics(IVD)
Infection Disease
Mental Disease
Neurodegenerative Disease
Obesity Treatment
OTC Drug
Pain
Pharmaceutical Companies
Prescription Drugs
Renal
Therapeutics / Diagnosis
Vaccines
Veterinary Medicine
Wound Care

* View All Categories
Japanese Korean Chinese
Home > Category > Pharmaceutical >

[Report]

The World Diabetes Market, 2006-2025 A Key Pharmaceutical Market of the Future

Published: 2007/10
Contact 24 hrs/day
Description

Table of Contents

Chapter 1. Executive Summary

  • 1.1 The Diabetes Market has High Potential
  • 1.2 Aims, Scope and Format of the Report
  • 1.3 Research Methodology

Chapter 2. Introduction to Diabetes

  • 2.1 Introduction of Diabetes
    • 2.1.1 Type 1 Diabetes Description
      • 2.1.1.1 Causation of Type 1 Diabetes
        • 2.1.1.1.1 Auto-Immune Response
        • 2.1.1.1.2 Genetic Abnormalities
        • 2.1.1.1.3 Viral Infections
        • 2.1.1.1.4 Cow' s Milk
      • 2.1.1.2 Symptoms of Type 1 Diabetes
        • 2.1.1.2.1 Hypoglycemia
        • 2.1.1.2.2 Ketoacidosis
    • 2.1.2 Type 2 Diabetes Description
      • 2.1.2.1 Causes of Type 2 Diabetes
        • 2.1.2.1.1 Insulin Resistance
        • 2.1.2.1.2 Genetic Factors
      • 2.1.2.2 Symptoms of Type 2 Diabetes
      • 2.1.2.3 Gestational Diabetes
      • 2.1.2.4 Maturity-Onset Diabetes in Youth
      • 2.1.2.5 Secondary Diabetes
      • 2.1.2.6 Pre-Diabetes
  • 2.2 Prevalence of Diabetes
    • 2.2.1. Diabetes Prevalence in the Seven Major Markets
    • 2.2.2 Diabetes Prevalence in Other Countries
    • 2.2.3 Mortality
    • 2.2.4 Diabetes Causes High Medication Expenditure
  • 2.3 Diabetes Risk Factors
    • 2.3.1 Type 1 Diabetes risk Factors
    • 2.3.2 Type 2 Diabetes Risk Factors
      • 2.3.2.1 Obesity and Physical Inactivity
      • 2.3.2.2 Aged of 40 Years or Older
      • 2.3.2.3 Family History of Diabetes
      • 2.3.2.4 Diabetes During Pregnancy
      • 2.3.2.5 Ethnicity
      • 2.3.2.6 Low Birth Weight
      • 2.3.2.7 Hypertension
    • 2.3.3 Metabolic Syndrome and its Relationship to Diabetes
  • 2.4 Diagnosing Diabetes
    • 2.4.1 Diagnostic Guidelines
    • 2.4.2 Diabetes Tests
      • 2.4.2.1 FPG (Fasting Plasma Glucose) Test
      • 2.4.2.2 OGTT (Oral Glucose Tolerance Test)
      • 2.4.2.3 Test for Glycosylated Haemoglobin
      • 2.4.2.4 Fructosamine
      • 2.4.2.5 Other Cautions for Diabetes Tests
  • 2.5 Health Consequence of Diabetes
    • 2.5.1 Cardiovascular Disease
    • 2.5.2 Blindness
    • 2.5.3 Nervous System Disease and Amputations
    • 2.4.4 Dental Disease
    • 2.5.6 Complications in Pregnancy

Chapter 3. The Treatments for Diabetes

  • 3.1 Introduction of Diabetes Treatments
    • 3.1.1 Introduction for Type 1 Diabetes Treatment
    • 3.1.2 Introduction for Type 2 Diabetes Treatments
  • 3.2 Insulin Classification
  • 3.3 Human Insulin
    • 3.3.1 Rapid-Acting Insulin
    • 3.3.2 Short-Acting Insulin
    • 3.3.3 Intermediate-Acting Insulin
    • 3.3.4 Long-Acting Insulin
    • 3.3.5 Ultra-Long-Acting Insulin
    • 3.3.6 Insulin Mixture
  • 3.4 Animal Insulin
  • 3.5 Oral anti-diabetes Drug (OADs) classification
    • 3.5.1 Alpha-Glucosidase Inhibitors (AGIs)
    • 3.5.2 Biguanides
    • 3.5.3 DDP-IV Inhibitors
    • 3.5.4 Meglitinides (Prandial Glucose Regulators: PGRs)
    • 3.5.5 Sulphonylureas
    • 3.5.6 Thiazolidiniones (TZDs)
  • 3.6 Others Drugs
    • 3.6.1 Incretin Mimetic (GLP-1 agonist)
  • 3.7 The Treatment of Type 2 Diabetes by Lifestyle Changes
    • 3.7.1 Diet and Weight Loss
    • 3.7.2 Exercise
    • 3.7.3 Monitoring blood glucose
    • 3.7.4 Daily Foot Care

Chapter 4. Global Diabetic Market Analysis

  • 4.1 Overview of Diabetes Market by Drug Class
  • 4.2 Current OAD Market Analysis
    • 4.2.1 Top OADs Analysis and Forecast
      • 4.2.1.1 Actos
      • 4.2.1.2 Avandia
  • 4.3 Current Insulin Market
    • 4.3.1 Leading Insulins Analysis and Forecast
      • 4.3.1.1 Lantus Preforms Strongly in Insulin Market
      • 4.3.1.2 Humalog
      • 4.3.1.3 NovoRapid/NovoLog (insulin aspart)
      • 4.3.1.4 NovoMixChapter

Chapter 5. Diabetes Market Analysis by Countries

  • 5.1 Overview of Global Market by Region
  • 5.2 Diabetes Market Analysis in Seven Major Countries
    • 5.2.1 Diabetes Market Trends 2003 to 2006
    • 5.2.2 OAD Market Analysis
    • 5.2.3 OADs Sales Analysis and Sales Forecast in the Seven Major Markets
      • 5.2.3.1 Sales Analysis
      • 5.2.3.2 Sales Forecast for OADs Market
    • 5.2.4 Human Insulin Market Analysis in Seven Major Markets
      • 5.2.4.1 Current Insulin Market Analysis
      • 5.2.4.2 Sales Forecast for Insulin in the Seven Major Markets
      • 5.2.4.3 Conclusion
  • 5.3 E7 Diabetes Market Analysis
    • 5.3.1 Current Market Analysis
    • 5.3.2 Analysis for the Four Leading Oral Antidiabetic Drugs in E7
    • 5.3.3 Sales Forecast in OADs Market in E7
    • 5.3.4 E7 Human Insulin Market Analysis
    • 5.3.5 Sales Forecast of E7 Insulin Market
    • 5.3.6 Conclusion

Chapter 6. Unmet Medical Needs for Diabetes Treatment and R&D

  • 6.1 Unmet Medical Needs for Diabetes Treatments
  • 6.2 New Development of Anti-Diabetic Drugs
    • 6.2.1 GLP-1 (Glucagon-Like Peptide-1) Inhibitors
    • 6.2.2 Future DDP-IV Iinhibitors
    • 6.2.3 SGLT (Sodium Glucose Co-Transporter Inhibitor)
    • 6.2.4 Glucokinase Activators
    • 6.2.5 Gluconeogesis Inhibitors
    • 6.2.6 PPAR ( Peroxisom Proliferators-Activated Receptors) Agonists
  • 6.3 Insulin Delivery Technologies
    • 6.3.1 Insulin Jet Injections
    • 6.3.2 Insulin Pens
    • 6.3.3 Injection Aids
    • 6.3.4 Insulin Jet Injectors
    • 6.3.5 External Insulin Pumps
  • 6.4 Introduction of New Delivery Technology
    • 6.4.1 Implantable Insulin Pumps
    • 6.4.2 Insulin Pills
    • 6.4.3 Transdermal Insulin
    • 6.4.4 Oral spray insulin
    • 6.4.5 Inhaled Insulin
    • 6.4.6 Insulin Patches
  • 6.5 Other New Technologies for Type 1 Diabetes
    • 6.5.1 Organ transplantation
    • 6.5.2 Stem cell Technology
  • 6.6 Blockbuster Anti-Diabetic Drugs
    • 6.6.1 Januvia (Sitagliptin)
    • 6.6.2 Galvus (Vildagliptin)
    • 6.6.3 Levemir (Insulin)
    • 6.6.4 Byetta (Exenatide)

Chapter 7. Key Players in the Global Diabetes Market

  • 7.1 Eli Lilly
    • 7.1.1 Marked Diabetes Product Portfolio
      • 7.1.1.1 Actos (Pioglitazone)
      • 7.1.1.2 Byetta (Exenatide)
      • 7.1.1.3 Humalog (Insulin Lispro (rDNA Origin))
      • 7.1.1.4 Humalog Mix 75/25 & 50/50
      • 7.1.1.5 Humulin (Human Insulin (rDNA Original))
    • 7.1.2 R&D Pipeline Analysis
      • 7.1.2.1 Arxxant (Ruboxistaurin)
      • 7.1.2.2 AIR Insulin
    • 7.1.3 Strategic Analysis
  • 7.2 GlaxoSmithKline
    • 7.2.1 Marketed Diabetes Product Portfolio
      • 7.2.1.1 Avandia (Rosiglitazone)
      • 7.2.1.2 Avandamet (Metformin/Rosiglitazone)
      • 7.2.1.3 Avandaryl (Rosiglitazone/ Glimepiride)
    • 7.2.2 R&D pipeline analysis
    • 7.2.3 Strategic Analysis
  • 7.3 Novo Nordisk
    • 7.3.1 Marketed Diabetes Product Portfolio
      • 7.3.1.1 Actraphane HM (Human Mixtard/Novolin Mixtard/Actraphane)
      • 7.3.1.2 NovoMix (Insulin Aspart)
      • 7.3.1.3 NovoRapid/ NovoLog (Human Insulin Aspart)
      • 7.3.1.4 Levemir (Insulin Detemir)
      • 7.3.1.5 INS. Protaphane HM (Human Insulin)
      • 7.3.1.6 INS. Actrapid HM (Human Insulin)
      • 7.3.1.7 Novonorm/Prandlin (Repaglinide)
    • 7.3.2 R&D Pipeline Analysis
      • 7.3.2.1 Liraglutide (NN2211)
      • 7.3.2.2 AERx iDMS (NN1998)
      • 7.3.2.3 NovoNorm/Metformin Fixed Combo
      • 7.3.2.4 E1-INT
      • 7.3.2.5 GLP1-INT
      • 7.3.2.6 NN9101
    • 7.3.3 Strategic Analysis
  • 7.4 Sanofi-Aventis
    • 7.4.1 Marked Diabetes Product Portfolio
      • 7.4.1.1 Apidra (Insulin Glulisine)
      • 7.4.1.2 Lantus (Insulin Glargine)
      • 7.4.1.3 Amaryl (Glimepiride)
      • 7.4.1.4 Daonil (Glibenclamide)& Diastabol (Miglitol)
    • 7.4.2 R&D Pipeline Analysis
      • 7.4.2.1 AVE0010
      • 7.4.2.2 AVE2268
      • 7.4.2.3 AVE0847
      • 7.4.2.4 AVE8134
      • 7.4.2.5 Others
    • 7.4.3 Strategic Analysis
  • 7.5 Takeda
    • 7.5.1 Marketed diabetes product portfolio
      • 7.5.1.1 Actos (Pioglitazone Hydrochloride)
      • 7.5.1.2 Basen (Voglibose)
    • 7.5.2 R&D Pipeline Analysis
      • 7.5.2.1 Alogliptin (SYR-322)&AD-4833-536
      • 7.5.2.2 Others
    • 7.5.3 Strategic Analysis
  • 7.6 Other Players in Diabetes Market
    • 7.6.1 Bayer
    • 7.6.2 Bistol-Mayers Squibb
    • 7.6.3 Pfizer
      • 7.6.3.1 Exubera(human insulin)
      • 7.6.3.2 R&D
      • 7.6.3.3 Strategies Analysis
    • 7.6.4 Merck KGaA
    • 7.6.5 Norvatis
    • 7.6.6 Servier

Chapter 8. SWOT Analysis for Global Diabetes Markets

  • 8.1 Unmet Market Needs
  • 8.2 SWOT Analysis
    • 8.2.1 Strengths
    • 8.2.2 Weaknesses
    • 8.2.3 Opportunities
    • 8.2.4 Threats
  • 8.3 Key Drivers of Growth
  • 8.4 Main Restraints of Growth

Chapter 9. Conclusion

  • 9.1 Diabetes is a Severe Condition with High Prevalence
  • 9.2 Existing Diabetes Treatment and the Promising New Drugs Delivery Technologies
    • 9.2.1 Existing Diabetes Treatment
    • 9.2.2 The Promising New Drugs Delivery Technologies
  • 9.3 The Optimistic Future for Diabetes Market from 2007 to 2012
    • 9.3.1 Overview of diabetes drugs
      • 9.3.1.1 OADs
      • 9.3.1.2 Insulins
    • 9.3.2 Regional Breakdown of Revenues in the Anti-Diabetic Market
      • 9.3.2.1 Major Seven Countries Will Have Substantial Growth
      • 9.3.2.2 E7 Increase Rapidly on Antidiabetics Treatments
  • 9.4 New Blockbusters Bring New Ways for Diabetes Treatments
  • 9.5 The Key Drivers and Main Restraints for Diabetes Market
  • 9.6 Outlook for the Future

List of Tables

  • Table 2.1 Prevalence of Type 1 and Type 2 diabetes in the 7 major markets, 2004-2005
  • Table 2.2 Top Ten Countries for Highest Estimated Cases of Diabetes, 2000 and 2030
  • Table 2.3 World Mortality Caused by Diabetes, 2002, 2004 and 2006
  • Table 2.4 Leading Causes of Death in the US 2004
  • Table 2.5 World Estimates of the Costs of Diabetes Care in 2003 ($M)
  • Table 2.6 Diabetes Expenditure in the Seven Major Countries ($M)
  • Table 2.7 Diabetes Expenditure in E7 ($M)
  • Table 2.8 Obese Population in Major Countries by Percentage (%)
  • Table 3.1 Types of Human Insulin on the Market 2007
  • Table 3.2 Oral Anti-diabetic Drugs 2007
  • Table 4.1 World Antidiabetic Drugs Sales ($M) 2003-2006
  • Table 4.2 Top Ten Antidiabetic Drugs Sales Performance ($M) 2003-2006
  • Table 4.3 World Top OADs Sales Performance ($M) 2003-2006
  • Table 5.1 World Diabetes Market by Countries 2003- 2006
  • Table 5.2 Sales Forecast for OADS in Seven Major Markets ($M)
  • Table 5.3 Insulin Sales Forecast in the Seven Major Countries ($M)
  • Table 5.4 OADs Sales Trends by E7s ($M) 2006
  • Table 5.5 OADs Distribution in E7s 2006
  • Table 5.6 OADs Sales Performance in E7 ($M)
  • Table 5.7 E7 OADS Sales Forecast ($M)
  • Table 5.8 Insulin Distribution in E7s 2006
  • Table 5.9 E7 Insulin Sales Performance ($M)
  • Table 5.10 E7 Insulin Sales Forecast ($M)
  • Table 5.11 Comparison of OADs and Insulin Sales in E7
  • Table 6.1 Overview of GLP-1 Agonists in Development 2007
  • Table 6.2 Overview of DDP-IV Inhibitors in Development
  • Table 6.3 Overview of PPARz in Development
  • Table 7.1 Eli Lilly Pipeline Development 2007
  • Table 7.2 GSK Pipeline Developments 2007
  • Table 7.3 Novo Nordisk Pipeline Developments 2007
  • Table 7.4 Sanofi-Aventis Pipeline Developments
  • Table 7.5 Takeda Pipeline Developments 2007
  • Table 7.6 Pfizer Pipeline Developments 2007
  • Table 8.1 SWOT Analysis for Diabetes Market
  • Table 9.1 Diabetes Markets in Major Seven Markets and E7s ($M)

List of Charts

  • Chart 2.1 US Diabetes Prevalence by Age 2005
  • Chart 4.1 World Diabetes Market 2006
  • Chart 4.2 Market Trends for Antidiabetic Drugs 2006
  • Chart 4.3 World Top OADs Sales 2006
  • Chart 4.4 World Market Trends of Top OADs 2006
  • Chart 4.5 World Actos Sales 2006
  • Chart 4.6 Sales Forecast of Actos ($M)
  • Chart 4.7 World Avandia Sales 2006
  • Chart 4.8 Sales Forecast for Avandia ($M)
  • Chart 4.9 World Insulin Sales 2006
  • Chart 4.10 Top Insulin Market Trends 2006
  • Chart 4.11 Lantus World Sales 2006
  • Chart 4.12 Sales Forecast of Lantus ($M)
  • Chart 4.13 World Humalog Sales 2006
  • Chart 4.14 Sales Forecast of Humalog ($M)
  • Chart 4.15 World NovoRapid Sales 2006
  • Chart 4.16 Sales Forecast of NovoRapid
  • Chart 4.17 World NovoMix Sales 2006
  • Chart 4.18 Sales Forecast of NovoMix ($M)
  • Chart 5.1 Global Diabetes Market by Economic Geography 2006
  • Chart 5.2 Diabetes Market Share in Seven Major Countries 2006
  • Chart 5.3 OADs and Insulins Sales Performance in Seven Major Countries ($M) 2006
  • Chart 5.4 OADs Market Share in Seven Major Countries 2006
  • Chart 5.5 Top OADs Sales in Seven Major Markets ($M) 2006
  • Chart 5.6 Top OADs Market Share in Seven Major Countries 2006
  • Chart 5.7 OADs Sales Distribution in Seven Major Markets 2006
  • Chart 5.8 Human Insulin Market in the Seven Major Countries 2006
  • Chart 5.9 Insulin Sales Performance by Seven Major Markets ($M) 2006
  • Chart 5.10 Top Insulin Market Share in the Seven Major Markets 2006
  • Chart 5.11 Insulins Market Distribution by Seven Major Markets 2006 ($M)
  • Chart 5.12 The Market Trends of OADs and Insulin in the E7 2006
  • Chart 5.13 E7 OADs Market Share 2006
  • Chart 5.14 E7s Leading OADs Performance by Sales Distribution 2006
  • Chart 5.15 Leading OADs Sales Performance by E7s ($M) 2006
  • Chart 5.16 E7s Insilin Market Share 2006
  • Chart 5.17 E7 Insulin Sales Performance ($M)
  • Chart 5.18 E7 Insulin Distribution 2006
  • Chart 6.1 Sales Forecast of Januvia ($M)
  • Chart 6.2 Sales Forecast of Galvus ($M)
  • Chart 6.3 Levemir World Sales 2006
  • Chart 6.4 Sales Forecast of Levemir ($M)
  • Chart 6.5 Sales Forecast of Byetta ($M)

Organisations mentioned in this report

  • Abbott
  • Activa
  • ADA (American Diabetes Association)
  • Aimsco
  • Ajinomoto
  • Alantos
  • Alkermes
  • Alphapharm
  • Altea Therapeutics
  • Amcyte
  • Amylin
  • Andrx
  • Animas
  • Apothecary Products
  • Astellas
  • AstraZeneca
  • Axordia
  • Bayer
  • Becton Dickinson
  • Bentley
  • Biocon
  • Bioject Corp
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Can-Am Care
  • CDC (US Centres for Disease Control and Prevention)
  • ConjuChem
  • CoreMed
  • Dainippon Sumitomo
  • Disetronic Medical Systems
  • Dong Sung Pharmaceuticals
  • Dr Reddy' s Laboratories
  • Eli Lilly
  • Emisphere Technologies
  • Equidyne
  • ESAD (European Association for the Study of Diabetes)
  • ESI (Essential Science Indicators)
  • Euromonitor
  • Flamel Technologies
  • Generex
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Human Genome Science
  • HypOview
  • IDF (International Diabetes Federation)
  • IMS
  • Innovata
  • Ivaz
  • International Obesity Taskforce
  • Kissei Pharmaceuticals
  • Kos Pharmaceutical
  • LifeScan
  • Living Cell Technologies
  • Lomonosov Moscow State University
  • MannKind
  • Massachusetts General Hospital
  • MEDgenesis
  • Medicool Inc.
  • Medicore
  • Medi-Ject Corp
  • Medtronic
  • Merck & Co.
  • Merck KGaA
  • Metabasis
  • Microdose
  • MiniMed
  • Mylan
  • NCEP
  • Nektar Therapeutics
  • Novartis
  • Novo Nordisk
  • OECD
  • Owen Mumford
  • Palco
  • Perrigo
  • Pfizer
  • Phenomix
  • Prosidion
  • Ranbaxy
  • Renovo
  • Roche
  • Sankyo Daiichi
  • Sanofi-Aventis
  • Serono
  • Servier
  • Takeda Pharmaceuticals
  • Tanabe
  • Teva
  • Transition
  • UltiMed
  • University of Arahus
  • University of Southern Denmark
  • ViaCell
  • Walgreens
  • Wal-Mart
  • Warner-Lambert Co.
  • Watson
  • Whittier Medical
  • WHO
  • Wockhardt
  • Zesteem
Description
[Report]
The World Diabetes Market, 2006-2025 A Key Pharmaceutical Market of the Future
Published: 2007/10
Published by : Visiongain Visiongain

Price:
US $ 2,545.00 PDF by E-mail (Single User)
US $ 5,878.00 PDF by E-mail (5 user License)
US $ 13,719.00 PDF by E-mail (Corporate User License)
>
How to Order?
Product Code : KT57512
Related Topics : Diabetes
Please inform me when related publications are released
InfoWatch

| Home | FAQ | Contact | E-mail Alert | About The Infoshop | Policies | Links | Site Map |
Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.